Any feedback?
Literature summary extracted from
- Inhibition of the activity of both domains of lysostaphin through peptidoglycan modification by the lysostaphin immunity protein (2010), Appl. Environ. Microbiol., 76, 6944-6946.
Application
| EC Number | Application | Comment | Organism |
|---|---|---|---|
| 3.4.24.75 | medicine | lysostaphin has potential for use as an antistaphylococcal agent for treatment of infections caused by antibiotic-resistant strains of Staphylococcus aureus | Staphylococcus simulans |
Natural Substrates/ Products (Substrates)
| EC Number | Natural Substrates | Organism | Comment (Nat. Sub.) | Natural Products | Comment (Nat. Pro.) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.24.75 | additional information | Staphylococcus simulans | resistance to lysostaphin is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges | ? | - |
? |  |
| 3.4.24.75 | Peptidoglycan + H2O | Staphylococcus simulans | - |
Fragments of peptidoglycan | - |
? | |
Organism
| EC Number | Organism | UniProt | Comment | Textmining |
|---|---|---|---|---|
| 3.4.24.75 | Staphylococcus simulans | P10547 | - |
- |
Substrates and Products (Substrate)
| EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
|---|---|---|---|---|---|---|---|
| 3.4.24.75 | additional information | resistance to lysostaphin is due to a FemABX-like immunity protein that inserts serines in place of some glycines in peptidoglycan cross bridges | Staphylococcus simulans | ? | - |
? | |
| 3.4.24.75 | Peptidoglycan + H2O | - |
Staphylococcus simulans | Fragments of peptidoglycan | - |
? | |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
